Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Copeptin as a marker of outcome after cardiac arrest : a sub-study of the TTM trial. / Düring, Joachim; Annborn, Martin; Cronberg, Tobias; Dankiewicz, Josef; Devaux, Yvan; Hassager, Christian; Horn, Janneke; Kjaergaard, Jesper; Kuiper, Michael; Nikoukhah, Homa Rafi; Stammet, Pascal; Undén, Johan; Wanscher, Michael Jaeger; Wise, Matt; Friberg, Hans; Nielsen, Niklas.
In: Critical Care, Vol. 24, 185, 04.2020.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Copeptin as a marker of outcome after cardiac arrest
T2 - a sub-study of the TTM trial
AU - Düring, Joachim
AU - Annborn, Martin
AU - Cronberg, Tobias
AU - Dankiewicz, Josef
AU - Devaux, Yvan
AU - Hassager, Christian
AU - Horn, Janneke
AU - Kjaergaard, Jesper
AU - Kuiper, Michael
AU - Nikoukhah, Homa Rafi
AU - Stammet, Pascal
AU - Undén, Johan
AU - Wanscher, Michael Jaeger
AU - Wise, Matt
AU - Friberg, Hans
AU - Nielsen, Niklas
PY - 2020/4
Y1 - 2020/4
N2 - Background: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest. Methods: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was 30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment (eCvSOFA) score. Results: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently associated with 30-day survival, hazard ratio 1.17 [1.06-1.28], p = 0.001; circulatory cause of death, odds ratio 1.03 [1.01-1.04], p = 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02-1.08], p < 0.001. Copeptin at 24 h was correlated with eCvSOFA score with rho 0.19 [0.12-0.27], p < 0.001. Conclusion: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure. Trial registration: Clinical Trials, NCT01020916. Registered November 26, 2009.
AB - Background: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest. Methods: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was 30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment (eCvSOFA) score. Results: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently associated with 30-day survival, hazard ratio 1.17 [1.06-1.28], p = 0.001; circulatory cause of death, odds ratio 1.03 [1.01-1.04], p = 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02-1.08], p < 0.001. Copeptin at 24 h was correlated with eCvSOFA score with rho 0.19 [0.12-0.27], p < 0.001. Conclusion: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure. Trial registration: Clinical Trials, NCT01020916. Registered November 26, 2009.
KW - Arginine vasopressin
KW - AVP protein human
KW - Biomarkers
KW - Copeptin
KW - Critical illness
KW - Humans
KW - Out-of hospital cardiac arrest
KW - Prognosis
KW - Survivors
U2 - 10.1186/s13054-020-02904-8
DO - 10.1186/s13054-020-02904-8
M3 - Journal article
C2 - 32345356
AN - SCOPUS:85084107249
VL - 24
JO - Critical Care
JF - Critical Care
SN - 1364-8535
M1 - 185
ER -
ID: 242716470